Fed Circuit invalidates Purdue oxycodone patent
The Federal Circuit has upheld a finding of the US Patent and Trademark Office, which rendered a Purdue Pharma oxycodone patent ineligible.
Neovasc adds two co-inventors to heart valve patents
Medical device company Neovasc has added two co-inventors to three of its patents, settling a dispute with a competitor, Edwards Lifesciences.
Hologics and Grifols agree $14m Enzo settlement
Enzo Life Sciences has entered into a settlement and licensing agreement with pharmaceutical companies Hologic and Grifols, ending a patent dispute between the parties.
Charpentier granted new CRISPR/Cas9 patent
ERS Genomics has announced a new CRISPR/Cas9 US patent for use of the gene-editing technology in a single guide format.
European Parliament approves SPC manufacturing waiver
The European Parliament has voted to approve the supplementary protection certificate manufacturing waiver, which will allow the stockpiling of generic versions of patented drugs.
Canadian generics plan could deter big pharma: report
Plans by Canada’s government to improve access to generic drugs could deter pharmaceutical companies from releasing brand medicine in the country, according to an internal government report.
US university treats cancer patients with CRISPR
The University of Pennsylvania has treated two cancer patients with CRISPR/Cas 9, a gene-editing technology that allows precise modifications to DNA.
Catalent to buy $1.2bn gene therapy company
Contract drug manufacturer Catalent has agreed to acquire Paragon Bioservices, a viral vector development and manufacturing partner for gene therapies, for $1.2 billion.
SCOTUS refuses to hear tribal immunity suit
The US Supreme Court has declined to hear a closely-watched case on tribal immunity involving pharmaceutical company Allergan and the Saint Regis Mohawk Tribe, a Native American tribe.
Fresenius files IPR against Amgen
Fresenius Kabi has submitted a petition for inter partes review of US patent number 9,856,287, a patent owned by Amgen.
